Overview

• T-cell immunotherapy firm's Q1 revenue fell sharply due to prior-year one-time revenue event

• Company posted Q1 net loss, reversing prior-year profit

• Operating expenses declined significantly after 2025 cost-reduction moves; cash runway extends into mid-2027

Outlook

• Operating expenses expected to decline significantly year-over-year in 2026

• Company expects cash and investments to fund operations into mid-2027

Result Drivers

• ONE-TIME REVENUE EVENT - Q1 revenue declined sharply as prior-year results included a one-time acceleration of revenue from transfer of tab-cel manufacturing responsibilities

• COST REDUCTIONS - Operating expenses declined significantly due to cost-reduction initiatives implemented in 2025

Company press release: ID:nBwbyb4bfa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Miss	$516,000	$2.85 mln (2 Analysts)
Q1 EPS		-$0.29
Q1 Net Income		-$4.15 mln
Q1 Operating Income		-$3.37 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $13.00, about 48.1% above its May 11 closing price of $8.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.